Novo Nordisk A/S (NYSE:NVO) Stock Rating Upgraded by Wall Street Zen

Novo Nordisk A/S (NYSE:NVO) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

NVO has been the subject of several other research reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. Finally, Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Down 0.1%

Shares of Novo Nordisk A/S stock opened at $44.71 on Friday. The company has a market capitalization of $199.63 billion, a P/E ratio of 10.50, a P/E/G ratio of 3.98 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a fifty day moving average of $39.73 and a 200 day moving average of $46.65. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.47 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently added to or reduced their stakes in NVO. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $25,000. Godfrey Financial Associates Inc. purchased a new position in Novo Nordisk A/S during the 4th quarter valued at $25,000. Scarborough Advisors LLC bought a new position in Novo Nordisk A/S in the 1st quarter valued at $26,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. Finally, American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $28,000. Institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
• Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
• Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
• Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
• Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
• Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
• Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
• Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.